Search results for "COPD"

showing 10 items of 483 documents

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD

2014

Nicola Scichilone,1 Alida Benfante,1 Luca Morandi,2 Federico Bellini,2 Alberto Papi21Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyAbstract: Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic diseases worldwide, characterized by a condition of variable degree of airway obstruction and chronic airway inflammation. A large body of evidence has demonstrated the importance of small airways as a pharmacological target in these clinical conditions. Despite a deeper understanding of the pathophysiologic…

Agonistmedicine.medical_specialtymedicine.drug_classReviewPharmacologySettore MED/10 - Malattie Dell'Apparato RespiratorioInternal medicineinhalational therapymedicineCOPDRespiratory systemAsthmaCOPDlcsh:R5-920small airwaysCOPD asthma inhalational therapy small airwaysLungbusiness.industryrespiratory systemAirway obstructionasthmamedicine.diseasePathophysiologyrespiratory tract diseasesmedicine.anatomical_structureFormoterolbusinesslcsh:Medicine (General)medicine.drug
researchProduct

β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD

2012

AbstractWe quantified TGF-β1 and acetylcholine (ACh) concentrations in induced sputum supernatants (ISSs) from 18 healthy controls (HC), 22 healthy smokers (HS) and 21 COPDs. ISSs from HC, HS and COPD as well as rhTGF-β1 were also tested in neutrophil adhesion and in mAChR2, mAChR3 and ChAT expression experiments in human bronchial epithelial cells (16-HBE). Finally, we evaluated the effects of Olodaterol (a novel inhaled β2-adrenoceptor agonist) and Tiotropium Spiriva®, alone or in combination, on neutrophil adhesion and mAChRs and ChAT expression in stimulated 16-HBE. The results showed that 1) TGF-β1 and ACh concentrations are increased in ISSs from COPD in comparison to HC and HS, and T…

Agonistmedicine.medical_specialtymedicine.drug_classchemistry.chemical_compoundInternal medicineTGF-β1Anticholinergic drugMuscarinic acetylcholine receptormedicineCOPDReceptorMolecular BiologyBeta2 long actingCOPDChemistryOlodaterolTiotropium bromidemedicine.diseaserespiratory tract diseasesEndocrinologyMolecular MedicineNeutrophilic inflammationBronchoconstrictionmedicine.symptomAcetylcholinemedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Airway Wall Thickness By HRCT Does Not Affect Airway Distensibility In Asthma And COPD

2013

Airways HRCT ASTHMA COPDSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly

2015

The prevalence of asthma in the most advanced ages is similar to that of younger ages. However, the concept that older individuals may suffer from allergic asthma has been largely denied in the past, and a common belief attributes to asthma the definition of "rare" disease. Indeed, asthma in the elderly is often underdiagnosed or diagnosed as COPD, thus leading to undertreatment of improper treatment. This is also due to the heterogeneity of clinical and functional presentations of geriatric asthma, including the partial loss of reversibility and the lower occurrence of the allergic component in this age range. The older asthmatic patients are also characterized the coexistence of comorbid …

Allergymedicine.medical_specialtyAgingAllergyImmunologyAlternative medicineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato RespiratorioAging; Allergy; Asthma; TherapymedicineImmunology and AllergyIntensive care medicineMolecular BiologyNon pharmacologicalAsthma...COPDbusiness.industryAging; Allergy; Asthma; Therapy; Molecular Biology; Immunology and Allergy; ImmunologySettore MED/09 - MEDICINA INTERNAmedicine.diseaseTreatment efficacyAsthmarespiratory tract diseasesClinical trialImmunologyTherapybusiness
researchProduct

Outcome and attitudes toward home tracheostomy ventilation of consecutive patients: a 10-year experience.

2008

Summary Objectives To describe survival, predictors of long-term outcome and attitudes in patients treated at home by tracheostomy-intermittent positive-pressure ventilation (TIPPV) for respiratory failure during a 10-year period (1995–2004). Methods Seventy-seven consecutive patients were treated by TIPPV at home. Patients were divided into three groups: neuromuscular, pulmonary, and non-pulmonary patients. Effects of TIPPV on survival, factors influencing outcome after TIPPV, and attitudes of patients and caregivers regarding mechanical ventilation were studied. Results Forty-one patients (53%) were neuromuscular, 19 (25%) were affected by pulmonary diseases, and 17 (22%) by non-pulmonary…

Artificial ventilationPulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySurvivalHome Nursingmedicine.medical_treatmentRespiratory failureIntermittent Positive-Pressure VentilationPulmonary Disease Chronic ObstructiveTracheotomyTracheostomyInternal medicinemedicineCOPDHumansProspective StudiesProspective cohort studySurvival rateAgedMechanical ventilationAged 80 and overCOPDbusiness.industryTracheostomy mechanical ventilationRespiratory diseaseAmyotrophic Lateral SclerosisNeuromuscular DiseasesMiddle Agedmedicine.diseaseRespiration ArtificialSurgerySurvival RateCaregiversRespiratory failureFemaleALSbusinessRespiratory InsufficiencyAttitude to HealthRespiratory medicine
researchProduct

GOLD Staging System is Appropriate to Predict Mortality in Older People With Chronic Obstructive Pulmonary Disease

2018

Abstract Introduction In the new GOLD classification the reduction of FEV1, expressed as percentage of predicted value (FEV1PP), is considered an important prognostic factor. However, the use of FEV1PP may introduce bias, especially if based on equations derived from populations different from the one under study. We evaluated how well the GOLD classification stratifies the mortality risk when FEV1PP is based on an equation developed in the same population that gave rise to cases, externally developed equations, or as FEV1 divided by cubed height (FEV1/Ht3). Methods We studied 882 participants aged ≥65 years. Bronchial obstruction was defined using a fixed cut-off of 0.7 for FEV1/FVC. Predi…

BODE indexPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratioFEV10302 clinical medicineElderlyInternal medicinemedicine030212 general & internal medicineGOLDeducationStaging systemCOPDeducation.field_of_studybusiness.industryChronic obstructive pulmonary diseaseHazard ratioGeneral Medicinerespiratory systemmedicine.diseaserespiratory tract diseases030228 respiratory systemQuartilebusiness
researchProduct

Pro-and anti-fibrotic molecule balance in the bronchial mucosa of stable COPD patients

2015

Background: The mechanisms of inducing fibrotic events and remodeling in the airways of COPD are incompletely studied. Objectives: To investigate the expression of cytokines involved in the pro- and anti-fibrotic events in stable COPD. Methods: Expression of CTGF, TGFβ1-2-3, TGFβRI, TGFβRII, LTBP-1, TRAP-1, BAMBI, PP2Cα, Smad2-3-6-7, pSmad2, pSmad3, pro-collagen-I and collagen-I was measured in the bronchial mucosa using immunohistochemistry and RT-qPCR. Results: TGFβ1 was increased in the epithelium and TGFβ3 in the submucosa of healthy smokers and mild/moderate COPD compared to healthy non-smokers. In all smokers and patients with COPD TGFβ3+ cells in the submucosa correlated significantl…

Basement membranemedicine.medical_specialtyCOPDbusiness.industrymedicine.diseaseGastroenterologyEpitheliumrespiratory tract diseasesCTGFmedicine.anatomical_structureSubmucosaInternal medicineReticular connective tissuemedicineImmunohistochemistryBAMBIbusiness5.2 Monitoring Airway Disease
researchProduct

ANTI-INFLAMMATORY ACTIVITY OF HSP60 IN HUMAN BRONCHIAL EPITHELIAL CELLS AND ITS INVOLVEMENT IN CHRONIC OBSTRUCTIVE PULMUNARY DISEASE

Bronchial InflammationSettore BIO/16 - Anatomia UmanaChaperonopathieCOPDHSP60
researchProduct